Microbiome Therapeutics Market by Type, Application, End-use

Description

List of Tables

[182 Pages Report] The Microbiome Therapeutics Market size was estimated at USD 131.09 million in 2023 and expected to reach USD 158.34 million in 2024, at a CAGR 21.44% to reach USD 510.87 million by 2030.

Microbiome therapeutics is an emergent area of medicine focused on using microorganisms or their components to prevent, treat, or cure disease. The human microbiome is the collection of trillions of commensal, symbiotic, and pathogenic microorganisms found in and on the human body. Microbiome therapeutics leverage the understanding of this complex ecosystem to develop products that can modify the microbiome in ways that contribute to health and combat disease. The market includes prebiotics, probiotics, postbiotics, and other interventions designed to treat and prevent diseases by influencing the microbiome. An increase in the prevalence of lifestyle-associated diseases, greater understanding of the microbiome in human health and disease, advancements in microbiological research technologies, and a supportive regulatory environment have driven market growth. Despite the potential, the microbiome therapeutics market faces certain challenges, including a lack of standardized regulations, difficulties in proving the efficacy of certain products, and the complexity of the microbiome. Intellectual property issues, high research costs, and reimbursement challenges are additional challenges across the market. Tailoring treatments based on an individual's unique microbiome composition holds promise for therapies' efficacy and success rates. Advances in genomic and metagenomic analytics allow for precision modulation of the microbiome. Moreover, partnerships between pharmaceutical and biotech firms specializing in microbiome research are expanding, potentially leading to new therapeutic discoveries and applications.

KEY MARKET STATISTICS
Base Year [2023]	USD 131.09 million
Estimated Year [2024]	USD 158.34 million
Forecast Year [2030]	USD 510.87 million
CAGR (%)	21.44%

Regional Insights

In North America, rising chronic disease prevalence and significant health consciousness among consumers have created a robust market for microbiome therapeutics. Advanced research facilities and substantial funding have led to groundbreaking microbial consortia and delivery technology patents. Key investments by major pharma and biotech firms and strategic partnerships propel the market across the region. EU nations collectively represent a vast market for microbiome therapeutics, underpinned by a strong regulatory framework and an emphasis on patient-centric care. Research and development are thriving, supported by European Commission initiatives like Horizon Europe. The European Investment Bank has also actively financed high-potential startups in this sector. Interest in personalized medicine is expanding in the Middle East, albeit with varying degrees across the region. Lifestyle diseases are rising, prompting investments into novel treatments, including microbiome-based therapies. However, the regulatory landscape and market access differ greatly between countries, influencing customer purchasing behavior and market penetration. Africa's market for microbiome therapeutics is nascent but holds potential, primarily due to an increased burden of infectious and lifestyle diseases. The Asia-Pacific (APAC) region presents a rapidly growing market for microbiome therapeutics, fueled by rising healthcare awareness and an increasing prevalence of lifestyle diseases. Countries such as China and Japan are at the forefront, with both nations investing heavily in microbiome research. The APAC market is characterized by many start-ups and local companies venturing into microbiome therapeutics.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Microbiome Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Increase in the prevalence of lifestyle-associated diseases
- Increasing use of microbiome sequencing capabilities for early disease detection and diagnosis
- Rising focus towards the human microbiome therapeutics

Market Restraints
- Lack of comprehensive research and limited expertise

Market Opportunities
- Growing public funds and driving R&D related to microbiome therapeutics
- Developing collaboration activities between pharmaceutical companies for the development of novel drugs

Market Challenges
- Concerns associated with regulatory and standardization

Market Segmentation Analysis
- Type: Emerging significance of for fecal microbiota transplantation severe bacterial infections
- Application: Increasing prevalence of infectious diseases driving the adoption of microbiome therapeutics
- End-use: Expanding application of microbiome therapeutics in hospitals & clinics to established safety and efficacy profiles

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Microbiome Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Microbiome Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Ferring Signs Microbiome R&D Partnership Deal with PharmaBiome

Ferring Pharmaceuticals has forged a strategic research and development collaboration with PharmaBiome, a Swiss biotech firm specializing in microbiome technologies. The partnership focuses on advancing next-generation microbiome-based therapies for gastrointestinal conditions. Ferring has secured exclusive rights to develop, produce, and commercialize the novel biotherapeutics arising from this alliance, all of which will benefit from PharmaBiome's cutting-edge platform capable of crafting specific bacterial consortia with desired therapeutic activities, including the NicheMap and an innovative co-cultivation technique. [Published On: 2023-12-11]

MaaT Pharma Joins Microbiome Therapeutics Innovation Group

MaaT Pharma has become a part of the Microbiome Therapeutics Innovation Group (MTIG), an alliance at the forefront of developing microbiome-based therapeutics. MaaT Pharma aligns seamlessly with MTIG's vision of transforming patient outcomes via regulatory and policy-driven solutions. The partnership converges MaaT Pharma's clinical progression with the joint expertise of MTIG's pioneering members, galvanizing efforts to convert extensive research into effective, FDA-approved treatments destined for clinical use. [Published On: 2023-07-20]

FDA Approves Seres' Microbiota Drug for Recurrent Gut Infection

The U.S. Food and Drug Administration has approved an innovative oral microbiome therapeutic by Seres Therapeutics designed to combat recurrent clostridioides difficile (C. diff.) infections. This therapeutic is crafted from thoroughly vetted human fecal matter, the drug encapsulates firmicutes spores essential for a robust microbiome that can deter C. diff colonization. [Published On: 2023-04-26]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Microbiome Therapeutics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Microbiome Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alveolus Bio, Assembly Biosciences, Inc, Axial Therapeutics, Inc., BioGaia AB, Enterome SA, Ferring B.V., Intralytix, Inc., Kanvas Biosciences, Locus Biosciences, Inc., MaaT Pharma, Microba Group, Microbiotica Limited, Osel, Inc., PharmaBiome AG, Pylum Biosciences, Rebiotix Inc., Second Genome Inc., Seres Therapeutics, Inc., Servatus Limited, Synlogic Inc., Theriva Biologics, Inc., Vedanta Biosciences, Inc., Viome, and Yakult Honsha Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Microbiome Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Fecal Microbiota Transplantation
- Microbiome Drugs
- Probiotics & Prebiotics

Application
- Autoimmune Diseases
- Gastrointestinal Disorders
- Infectious Diseases
- Metabolic Disorders

End-use
- Academic & Research Institutions
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-ED54C46E807C

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increase in the prevalence of lifestyle-associated diseases
  - 5.1.1.2. Increasing use of microbiome sequencing capabilities for early disease detection and diagnosis
  - 5.1.1.3. Rising focus towards the human microbiome therapeutics
- 5.1.2. Restraints
  - 5.1.2.1. Lack of comprehensive research and limited expertise
- 5.1.3. Opportunities
  - 5.1.3.1. Growing public funds and driving R&D related to microbiome therapeutics
  - 5.1.3.2. Developing collaboration activities between pharmaceutical companies for the development of novel drugs
- 5.1.4. Challenges
  - 5.1.4.1. Concerns associated with regulatory and standardization
5.2. Market Segmentation Analysis
- 5.2.1. Type: Emerging significance of for fecal microbiota transplantation severe bacterial infections
- 5.2.2. Application: Increasing prevalence of infectious diseases driving the adoption of microbiome therapeutics
- 5.2.3. End-use: Expanding application of microbiome therapeutics in hospitals & clinics to established safety and efficacy profiles
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Microbiome Therapeutics Market, by Type

6.1. Introduction
6.2. Fecal Microbiota Transplantation
6.3. Microbiome Drugs
6.4. Probiotics & Prebiotics

7. Microbiome Therapeutics Market, by Application

7.1. Introduction
7.2. Autoimmune Diseases
7.3. Gastrointestinal Disorders
7.4. Infectious Diseases
7.5. Metabolic Disorders

8. Microbiome Therapeutics Market, by End-use

8.1. Introduction
8.2. Academic & Research Institutions
8.3. Hospitals & Clinics

9. Americas Microbiome Therapeutics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Microbiome Therapeutics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Microbiome Therapeutics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Ferring Signs Microbiome R&D Partnership Deal with PharmaBiome
- 12.3.2. MaaT Pharma Joins Microbiome Therapeutics Innovation Group
- 12.3.3. FDA Approves Seres' Microbiota Drug for Recurrent Gut Infection
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio